VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Nektar Therapeutics (NKTR) Total Return Calculator with Dividends Reinvested

Nektar Therapeutics

Popular:

The total return for Nektar Therapeutics (NKTR) stock is +783.59% over the past 12 months. So far it's up 95.97% this year. The 5-year total return is -69.37%, meaning $10,000 invested in NKTR stock 5 years ago would be worth $3,063 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in NKTR 1 year ago, it would be worth $93,711 today — you'd have gained $83,711.

With Dividends Reinvested$93,711+837.11%

Price Only (No DRIP)$93,711+837.11%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in NKTR

1Y$88,359+$78,359 (+783.6%)783.6% CAGR

3Y$73,671+$63,671 (+636.7%)94.6% CAGR

5Y$3,063-$6,937 (-69.4%)-21.1% CAGR

10Y$4,240-$5,760 (-57.6%)-8.2% CAGR

15Y$5,633-$4,367 (-43.7%)-3.8% CAGR

20Y$2,502-$7,498 (-75.0%)-6.7% CAGR

30Y$6,261-$3,739 (-37.4%)-1.5% CAGR

Nektar Therapeutics did not pay dividends during this period. Total return = price return.

Loading NKTR total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+95.97%	—	+95.97%	—	$19,597
1Y	+783.59%	783.59%	+783.59%	—	$88,359
3Y	+636.71%	94.58%	+636.71%	—	$73,671
5Y	-69.37%	-21.07%	-69.37%	—	$3,063
10Y	-57.60%	-8.22%	-57.60%	—	$4,240
15Y	-43.67%	-3.75%	-43.67%	—	$5,633
20Y	-74.98%	-6.69%	-74.98%	—	$2,502
30Y	-37.39%	-1.55%	-37.39%	—	$6,261

Risk & Highlights

Best Year+370.61%2017

Worst Year-83.46%2022

Max Drawdown-46.54%2025-11-26 → 2026-02-05 · Recovered 2026-02-11

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+58.87%	+58.87%	—	+0.41%	+58.5pp
2025	+193.20%	+193.20%	—	+16.64%	+176.6pp
2024	+56.39%	+56.39%	—	+24.00%	+32.4pp
2023	-74.19%	-74.19%	—	+24.81%	-99.0pp
2022	-83.46%	-83.46%	—	-19.95%	-63.5pp

NKTR outperformed the S&P 500 by 752.27pp over the past year (+783.59% vs +31.32%).

Loading summary...

NKTR Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
NKTRNektar Therapeutics	$1.7B	+13.9%	+96.0%	+783.6%	—	+636.7%	-69.4%	-57.6%
HALOHalozyme Therapeutics, Inc.	$7.8B	+5.2%	-5.6%	+11.7%	—	+119.1%	+39.1%	+598.4%
ARWRArrowhead Pharmaceuticals, Inc.	$11.1B	+29.5%	+16.7%	+505.0%	—	+95.6%	+20.5%	+1315.7%
ALNYAlnylam Pharmaceuticals, Inc.	$40.4B	-8.3%	-24.3%	+12.3%	—	+44.3%	+129.4%	+445.5%
IONSIonis Pharmaceuticals, Inc.	$12.7B	+3.4%	-3.5%	+141.2%	—	+118.4%	+105.9%	+126.0%
EXELExelixis, Inc.	$12.4B	+10.7%	+11.7%	+32.1%	—	+155.9%	+109.7%	+916.7%
INCYIncyte Corporation	$19.9B	+5.3%	-1.5%	+67.5%	—	+51.8%	+21.3%	+41.3%
RCUSArcus Biosciences, Inc.	$2.6B	+16.9%	+11.6%	+220.2%	—	+31.0%	-13.7%	+52.9%
IMVTImmunovant, Inc.	$5.8B	+15.2%	+10.7%	+107.2%	—	+48.4%	+73.9%	+188.1%
CLDXCelldex Therapeutics, Inc.	$2.3B	+9.6%	+27.3%	+86.9%	—	+3.1%	+29.4%	-34.3%
AGENAgenus Inc.	$137M	+3.2%	+20.4%	+31.0%	—	-87.8%	-93.1%	-93.5%

Compare:NKTR vs HALO NKTR vs ARWR NKTR vs ALNY NKTR vs HALO vs ARWR

About NKTR Dividend Returns

Nektar Therapeutics (NKTR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of NKTR over the past year?

Nektar Therapeutics (NKTR) delivered a return of 783.59% over the past year. Since NKTR does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in NKTR be worth today?

A $10,000 investment in Nektar Therapeutics one year ago would be worth $88,359 today, representing a gain of $78,359.

Q3Does NKTR pay dividends?

Nektar Therapeutics (NKTR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For NKTR, the total return equals the price-only return.

Q4Did NKTR beat the S&P 500?

Yes, Nektar Therapeutics (NKTR) outperformed the S&P 500 by 752.27 percentage points over the past year. NKTR delivered a total return of 783.59%, compared to the S&P 500's 31.32%. This 752.27pp alpha means investors in NKTR earned more than a passive S&P 500 index fund.

Q5What is NKTR's worst drawdown?

Nektar Therapeutics (NKTR) experienced a maximum drawdown of -46.54% over the past year, declining from its peak on 2025-11-26 to its trough on 2026-02-05. The stock recovered to its prior peak by 2026-02-11. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is NKTR's long-term total return over 10, 20, or 30 years?

Here are Nektar Therapeutics (NKTR)'s long-term returns with dividends reinvested. Over 10 years, the total return is -57.6% (-8.2% CAGR) — $10,000 would have grown to $4,240. Over 20 years: -75.0% total return (-6.7% CAGR) — $10,000 → $2,502. Over 30 years: -37.4% total return (-1.5% CAGR) — $10,000 → $6,261. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was NKTR's best and worst year?

Nektar Therapeutics's best calendar year was 2017 with a total return of 370.6%. Its worst year was 2022 with a total return of -83.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 454.1 percentage points.